Reliance Life Sciences (RLS), part of India’s largest conglomerate, is expected to start Phase I clinical studies of its indigenous Covid-19 vaccine soon, reports Rupali Mukherjee. The Subject Expert Committee, which advises the drug regulator on vaccines and new drugs, reviewed the company’s application and is learnt to have recommended it for approval on Thursday. A formal nod to conduct trials of the two-dose jab is expected over the next few days, sources told TOI.
The vaccine under development is a recombinant protein-based Covid-19 vaccine, and is expected to be launched by the first quarter 2022. The company started the development process last year, with the vaccine entering the pre-clinical stage in October
The vaccine is being developed at the company’s Navi Mumbai facility, and is expected to be “competitively priced”.
Reliance Life Sciences seeks nod for vaccine trial – Times of India